Company intelligence / Profile preview

Pentaomix

Ownership: Private
Development stage: Preclinical

Overview

Pentaomix is developing a novel digital pathology system that allows pathologists to diagnose cancers—including over 80 lymphoma sub-types—using a single slide. The technology enables visualization and co-localization of multiple biomarkers simultaneously, aiming to improve diagnostic speed and accuracy compared to current multi-slide methods. Clinical results are not yet published; the company is focused on development and validation.

Therapeutic areas: Oncology
Modalities: DeviceDigital pathology platform
Industry: Pathology

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Pentaomix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pentaomix.

Explore the full profile